Fig. 8: BiA9*2_HF loaded with tagged neoantigen from an experimental colorectal model leads to superior anti-tumor responses compared to CpG as adjuvant and displays complete tumor regression upon dose elevation.
A, B Tumor volumes over time and survival analysis in mice treated with indicating groups using 30 µg of BiA9*2_HF and 1.44 µg (450pmol) of pTag9aa-Apgk295-313 peptide or 20 µg of CpG with 6.4ug (2000pmol) of pTag9aa-Adpgk295-313. A Vehicle n = 8, CpG + pTag9aa-Adpgk295-313 n = 8, BiA9*2_HF n = 8 and BiA9*2_HF + pTag9aa- Adpgk295-313 n = 8, in Biocytogen mice. *p = 0.0397 calculated with the Kruskal-Wallis test with Dunn’s multiple comparison test. B Vehicle n = 6, CpG + pTag9aa-Adpgk295-313 n = 6, BiA9*2_HF n = 6 and BiA9*2_HF + pTag9aa- Adpgk295-313 n = 5. ns = non-significant calculated with Kaplan-Meier survival analysis with log-rank test. C Individual tumor growth over time in the MC38 model with arrows indicating therapy administration. Vehicle n = 8, BiA9*2_HF n = 8, BiA9*2_HF + pTag7aa- Adpgk295-313 n = 10 and BiA9*2_HF + pTag9aa- Adpgk295-313 n = 10, tgCD40 from Biocytogen. D Survival analysis of mice treated with 30 µg BiA9*2_HF at the first and third injection and 90 µg at the second injection, either alone or in combination with 1.44 µg (450pmol) pTag9aa-Adpgk295-313 or 1.32 µg (450pmol) pTag7aa-Adpgk295-313. At day 14, the vehicle group received 30 µg BiA9*2_HF with 1.44 µg (450pmol) pTag9aa-Adpgk295-313. Vehicle n = 4, BiA9*2_HF n = 8, BiA9*2_HF + pTag7aa- Adpgk295-313 n = 7 and BiA9*2_HF + pTag9aa- Adpgk295-313 n = 8. ****p = < 0.0001 calculated with Kaplan-Meier survival analysis with log-rank test. Data is shown as mean with ± SEM (A).
